These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22616099)

  • 21. The intricate association between gut microbiota and development of type 1, type 2 and type 3 diabetes.
    Bekkering P; Jafri I; van Overveld FJ; Rijkers GT
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1031-41. PubMed ID: 24138599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Probiotics, prebiotics, synbiotics and insulin sensitivity.
    Kim YA; Keogh JB; Clifton PM
    Nutr Res Rev; 2018 Jun; 31(1):35-51. PubMed ID: 29037268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?
    Esteve E; Ricart W; Fernández-Real JM
    Curr Opin Clin Nutr Metab Care; 2011 Sep; 14(5):483-90. PubMed ID: 21681087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective.
    Han JL; Lin HL
    World J Gastroenterol; 2014 Dec; 20(47):17737-45. PubMed ID: 25548472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in intestinal microecology: the microbiome, prebiotics, and probiotics.
    Floch MH
    Nutr Clin Pract; 2012 Apr; 27(2):193-4. PubMed ID: 22383451
    [No Abstract]   [Full Text] [Related]  

  • 26. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN MANAGEMENT OF OBESITY AND PREDIABETES: REVIEW OF RANDOMIZED CONTROLLED TRIALS.
    Barengolts E
    Endocr Pract; 2016 Oct; 22(10):1224-1234. PubMed ID: 27409822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intestinal microbiota and novel therapeutic perspectives for the treatment of metabolic diseases].
    Burcelin R; Chabo C; Blasco-Baque V; Sérino M; Amar J
    Med Sci (Paris); 2013; 29(8-9):800-6. PubMed ID: 24005637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting gut microbiota in obesity: effects of prebiotics and probiotics.
    Delzenne NM; Neyrinck AM; Bäckhed F; Cani PD
    Nat Rev Endocrinol; 2011 Aug; 7(11):639-46. PubMed ID: 21826100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metabolic syndrome and intestinal microflora: what overall?].
    Plotnikova EIu; Krasnov OA
    Eksp Klin Gastroenterol; 2014; (12):64-73. PubMed ID: 26058115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Gut microbiota, responsible for our body weight?].
    Pataky Z; Bobbioni-Harsch E; Hadengue A; Carpentier A; Golay A
    Rev Med Suisse; 2009 Mar; 5(196):662-4, 666. PubMed ID: 19462608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of probiotics on bile acids in diseases and aging.
    Sivamaruthi BS; Fern LA; Rashidah Pg Hj Ismail DSN; Chaiyasut C
    Biomed Pharmacother; 2020 Aug; 128():110310. PubMed ID: 32504921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional interactions between the gut microbiota and host metabolism.
    Tremaroli V; Bäckhed F
    Nature; 2012 Sep; 489(7415):242-9. PubMed ID: 22972297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
    Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
    Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microbiota and diabetes: an evolving relationship.
    Tilg H; Moschen AR
    Gut; 2014 Sep; 63(9):1513-21. PubMed ID: 24833634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?
    Musso G; Gambino R; Cassader M
    Diabetes Care; 2010 Oct; 33(10):2277-84. PubMed ID: 20876708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel opportunities for the exploitation of host-microbiome interactions in the intestine.
    Claes IJ; Vargas García CE; Lebeer S
    Curr Opin Biotechnol; 2015 Apr; 32():28-34. PubMed ID: 25448229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From role of gut microbiota to microbial-based therapies in type 2-diabetes.
    Ebrahimzadeh Leylabadlo H; Sanaie S; Sadeghpour Heravi F; Ahmadian Z; Ghotaslou R
    Infect Genet Evol; 2020 Jul; 81():104268. PubMed ID: 32126303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?
    Diamant M; Blaak EE; de Vos WM
    Obes Rev; 2011 Apr; 12(4):272-81. PubMed ID: 20804522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A core gut microbiome in obese and lean twins.
    Turnbaugh PJ; Hamady M; Yatsunenko T; Cantarel BL; Duncan A; Ley RE; Sogin ML; Jones WJ; Roe BA; Affourtit JP; Egholm M; Henrissat B; Heath AC; Knight R; Gordon JI
    Nature; 2009 Jan; 457(7228):480-4. PubMed ID: 19043404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The microbiota of intestine. The role in development of various pathologies].
    Kuznetsova EE; Gorokhova VG; Bogorodskaya SL
    Klin Lab Diagn; 2016 Oct; 61(10):723-6. PubMed ID: 30615347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.